stockrowRevvity Inc.
RVTY Healthcare Diagnostics & Research
Revvity Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 3.67% from fiscal 2024.
- Revenue
- +4.29%
- EPS
- +2.17%
- Free cash flow
- +27.0%
- Total debt
- −18.1%
Quarter to September 2026, against a year earlier
Follow RVTY
Alert me
Revvity Inc. (RVTY) Revenue growth
Revvity Inc.'s revenue growth over the twelve months to 30 September 2026 was 4.56%, up 0.9 percentage points from fiscal 2025 (3.67%). Over the past ten years it has ranged from −17.0% (fiscal 2023) to 43.7% (fiscal 2021); the current reading is higher than 64% of that period. That is below the Diagnostics & Research industry median of 8.99% and below the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 3.67% | 3.51 |
| FY2024 | 0.16% | 17.11 |
| FY2023 | −17.0% | (3.47) |
| FY2022 | −13.5% | (57.21) |
| FY2021 | 43.7% | 51.37 |
| FY2020 | −7.64% | (11.44) |
| FY2019 | 3.80% | (19.28) |
| FY2018 | 23.1% | 16.39 |
| FY2017 | 6.69% | 6.18 |
| FY2016 | 0.51% | (1.18) |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 4.29% | 2.98 |
| Jun 2026 | 1.31% | (5.66) |
| Mar 2026 | 6.97% | 1.12 |
| Dec 2025 | 5.85% | 3.67 |
| 43 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| GH Guardant Health, Inc. compare | 41.7% |
| MEDP Medpace Holdings, Inc. compare | 20.4% |
| DGX Quest Diagnostics Incorporated compare | 9.13% |
| LH Labcorp Holdings Inc. compare | 6.02% |
| ILMN Illumina, Inc. compare | 5.83% |
| RVTY Revvity Inc. | 4.56% |
| QGEN QIAGEN N.V. compare | 2.96% |
| ICLR ICON PLC compare | 1.82% |
| CRL Charles River Laboratories International, Inc. compare | −1.16% |
| Diagnostics & Research industry median | 8.99% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on RVTY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement